RxSight 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 total company revenue was $24.6 million, down 19% from $30.3 million in the prior-year period.
- LAL procedure volume was $22.8 million of revenue and 23,128 units, down 11% from 26,045 units in the prior-year period, primarily reflecting ongoing competitive pressures.
- Gross margin was 73.6%, compared with 79.9% in the prior-year period, primarily due to increased inventory reserves partially offset by favorable product mix; the prior-year margin was uncharacteristically high because of sell-through of lower-cost LAL and LDD inventory.
- SG&A expenses were $27.4 million, in line with the prior-year period, and R&D expenses were $9.2 million, compared with $9.1 million in the third quarter of 2025.
- Net loss was $16.2 million, or $0.39 per basic and diluted share, based on 41.7 million weighted average shares outstanding; stock-based compensation was $7.6 million, resulting in an adjusted net loss of $8.6 million, or $0.21 per share.
- Cash, cash equivalents, and short-term investments totaled $254.7 million at quarter-end, including $60 million received in connection with the Alcon collaboration upfront payment.
- The company reported three LDD sales and one rental in the third quarter and said LDD ASPs remained stable.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. Thank you for joining us, and welcome to RxSight Third Quarter 2026 Earnings Conference Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Oliver Moravcevic, VP of Investor Relations.
Please go ahead. Thank you, operator.
With me on the call today are RxSight President and Chief Executive Officer Aziz Mottiwala and Chief Financial Officer Mark Wilterding. Earlier today, RxSight released financial results for the three months ended September 30, 2026. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that comments and responses to questions during today's call reflect management's views as of today and will include forward-looking and opinion statements, including predictions, estimates, plans, and expectations. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued today and in our filings with the Securities and Exchange Commission, or SEC. Our SEC filings can be found on our website or the SEC's website.
Investors are cautioned not to place undue reliance on forward-looking statements, and we disclaim any obligation to update or revise these forward-looking statements, except as may be required by law. We will also discuss certain non-GAAP financial measures. Disclosures regarding non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that this conference call will be available for audio replay on our investor relations website. With that, I will turn the call over to Aziz.
Thank you, Oliver, and good afternoon, everyone. I've been at RxSight for just over 90 days, and I want to start by saying how impressed I am with the team and what we've accomplished in such a short time. What has stood out to me most is the passion our people have for our technology, their commitment to our patients, and the determination to position the company for long-term success. We have a strong foundation of talent across the organization, and I'm equally excited about the new leadership and capabilities we've added over the past several months. During this time, I've also prioritized being in the field and meeting with our key physician customers. Their feedback has been consistent and reinforced my conviction in RxSight's technology. They strongly believe in the benefits of the Light Adjustable Lens and the differentiated visual outcomes LAL delivers.
These conversations have also provided valuable insights into how physicians are using our technology and where we have opportunities to better support their practices and drive broader adoption. When we spoke last quarter, I outlined my three initial focus areas: develop a deeper understanding of the business, identify the underlying challenges and opportunities, and determine where we could have the greatest impact. I also committed to providing additional clarity on our strategy and the actions we will take to move the business forward. The bulk of that initial assessment is now complete, and our priorities are clear: strengthen the U.S. LAL business, advance our next-generation adjustable lens pipeline, and execute on the significant opportunity represented by our collaboration with Alcon. Over the last three months, we've taken important steps to advance each of these priorities while maintaining financial discipline and building a more efficient operating model.
Let me begin with our U.S. commercial business. We have a substantial install base and a large community of physicians who believe strongly in the value of adjustability. Our opportunity is to drive deeper adoption through more frequent and higher-quality engagement, clearer education around the advantages of LAL, better integration into practice workflow, and stronger peer-to-peer advocacy. We see many of these elements already working very well in our highest-utilizing practices, and our goal is to develop a scalable and repeatable model that allows a broader group of customers to achieve similar success. Turning that model into more consistent execution across our customer base requires the right leadership and capabilities, and we have made significant progress enhancing both. Most recently, we strengthened our commercial leadership team with the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as EVP of Sales and Commercial Strategy.
Both are highly experienced leaders with strong track records building and executing commercial strategies across a broad range of ophthalmic businesses. I've had the pleasure of working with Taryn before, and I know firsthand the leadership and commercial expertise she brings. Her unique background spanning both commercial leadership and medical affairs is particularly valuable as we focus on strengthening physician engagement and driving broader LAL adoption. I've also known Frank for many years and have long respected his reputation as a highly customer-focused leader in the eye care industry. Since announcing their appointments a couple weeks ago, several key customers have reached out to express their excitement about these additions to our team. I share that enthusiasm and look forward to the positive impact that Taryn and Frank will have with our talented team and highly differentiated LAL technology.
During this time, we've also made significant progress implementing our sales force expansion efforts, nearly doubling the team size. I've had the opportunity to meet many of our new sales representatives as they progress through their initial onboarding and training, and I've been extremely impressed by the quality of the talent we have brought into the organization. The majority of them bring extensive eye care experience and have well-established relationships with the physicians and practices we serve. As they complete training and establish themselves in their respective territories, we expect their impact to build over time. The rationale for the expansion is straightforward. It allows us to engage more frequently with our customers, build stronger relationships, and drive deeper LAL utilization across our existing user base.
This higher-touch approach also gives us more opportunities to highlight LAL's unique ability to adjust and personalize vision after surgery to better meet each patient's needs, an important distinction in an increasingly competitive environment. I also witnessed the value of our differentiation firsthand while attending the recent American Academy of Ophthalmology meeting in New Orleans. It was particularly encouraging to see the breadth of physician-led discussion around adjustability throughout the scientific program. A consistent theme across these presentations was that adjustability empowers physicians to deliver strong, personalized visual outcomes across several different patient populations. These presentations made it evident that physicians continue to get strong outcomes in patients with prior corneal refractive surgery and report getting excellent results using blended vision strategies.
Beyond the scientific presentations, I had the opportunity to personally meet with hundreds of surgeons during the conference and was set out with their continued enthusiasm for LAL and the outcomes it delivers. One physician interaction that stood out to me was an ophthalmologist who shared that he had recently chosen LAL for his own brother, a busy attorney with demanding visual needs and high expectations for his vision. He went on to tell me his brother's spectacle-free and how thrilled he is with the results. To me, that kind of personal endorsement confirms that physicians truly believe in the differentiated outcomes LAL provides. In addition to the opportunity we see with the current LAL platform, we are advancing our next-generation adjustable lens pipeline, focusing on innovations designed to expand the population of patients who will benefit from adjustability, reduce workflow, and further enhance performance.
We're also pleased with the strong start to our collaboration with Alcon. Our teams are closely aligned and making great progress. Importantly, we have now passed the initial 120-day period under our agreement, and we're excited to continue advancing this long-term partnership. Together with our existing LAL platform and next-generation pipeline, this collaboration has the potential to bring the benefits of postoperative adjustability to the majority of patients across the premium IOL market. Finally, over the past several months, we have taken an extensive look at our investment priorities and sharpened our focus on operating more efficiently. This process involved some difficult decisions, which we did not take lightly.
As part of that effort, we recently completed a significant restructuring that is expected to generate meaningful cost savings in our base business while allowing us to invest in the areas we believe are important for long-term value creation, particularly our next-generation pipeline and our partnership with Alcon. With that, I'll turn the call over to Mark to provide additional detail and review our third-quarter financial results.
Thank you, Aziz, and good afternoon, everyone. Third-quarter total company revenue of $24.6 million declined 19% compared with $30.3 million in the prior year period. LAL procedure volume accounted for $22.8 million of revenue in Q3, with the balance attributable to LDD and service revenue. Third-quarter LAL procedure volume of 23,128 units declined 11% compared with 26,045 units in the prior year period, primarily reflecting ongoing competitive pressures. Third-quarter gross margin was 73.6% compared with 79.9% in the prior year period, primarily reflecting an increase in inventory reserves, partially offset by favorable product mix. In the third quarter of last year, gross margin was uncharacteristically high, reflecting the sell-through of lower-cost LAL and LDD inventory. Third-quarter SG&A expenses were $27.4 million, in line with the prior year period.
Research and development expenses were $9.2 million, consistent with $9.1 million reported in the third quarter of 2025. We reported a net loss of $16.2 million, or $0.39 per basic and diluted share, based on 41.7 million weighted average shares outstanding. Stock-based compensation was $7.6 million, resulting in an adjusted net loss of $8.6 million, or $0.21 per share. We ended the third quarter with cash equivalents, and short-term investments of $254.7 million, including $60 million received in connection with the Alcon collaboration upfront payment. Turning to the restructuring Aziz discussed, I want to provide some additional perspective on the financial implications of these changes. Following a comprehensive bottom-up review, we implemented changes to our cost structure and resource allocation across manufacturing, corporate functions, and international operations.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
